ATHERSYS EXTENDS PARTNERSHIP WITH BRISTOL-MYERS SQUIBB TO PROVIDE DRUG TARGETS

Athersys Inc. announced today that it has extended its existing alliance with Bristol-Myers Squibb Company (NYSE: BMY - News) to apply its patented RAGE technology to provide Bristol-Myers Squibb with additional validated drug targets for high-throughput screening and lead optimization in multiple therapeutic areas. The new agreement will extend the alliance for up to three years with a guaranteed minimum number of targets to be supplied by Athersys annually.
Yahoo News